Regulatory Approval Or License Win
Expected: Q1 FY27HIGH confidence
What: MIP Implementation: $25/kg for Pen-G
Impact: Meaningful uplift in profitability
“The policy change will act as a very important and positive catalyst event for the company.”
Aurobindo Pharma Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +26.2%Average10w Streak
In , Aurobindo Pharma Ltd (Pharma - Formulators) is outperforming Nifty 500 with +26.2% relative strength. Fundamentals: Average. On a 10-week streak.
Aurobindo Pharma Ltd Key Facts
- PE Ratio
- 24.5x
- Market Cap
- ₹86,383 Cr
- PAT Growth YoY
- +8%
- Revenue Growth YoY
- +8%
- OPM
- 21.0%
- RS vs Nifty 500
- +26.2%
PE: At PeakNeutral
What's Happening
📊PE near cycle highs — limited room for further expansion
🌐FII stake decreased 2.4% this quarter
🏛️DII accumulation — stake up 2.5%
💰Trading 32% above estimated fair value — significant premium
Earnings Acceleration Triggers
1. Regulatory Approval Or License Win
Q1 FY27HIGH
2. Operating Leverage Inflection
March 2026HIGH
3. Geographical Expansion
End of FY26MEDIUM
Key Risks
1. Eugia III facility received procedural and technical observations from the USFDA
HIGH2. Significant depreciation of the Rupee against the USD and Euro
MEDIUM3. Predatory pricing in 6APA internationally
MEDIUMSector-Specific Signals
U.S. Formulation Revenue$420 million
Europe Revenue Growth (YoY)27%+27%
U.S. Injectable Sales Growth (YoY)17%+17%
Pen-G Annualized Production10,000 MT
Key Numbers
PAT Growth YoY
+8%
Inflection Up
Revenue YoY
+8%
Stable
Operating Margin
21.0%
+100 bps YoY
PE Ratio
24.5
Current Price
₹1,487
Dividend Yield
0.27%
Fundamental Score
49/100
Average
3Y PAT CAGR
+10%
Market Cap
86.4K Cr
Valuation
Significantly Overvalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
Why Are Aurobindo Pharma Ltd's Earnings Accelerating?
Based on Q3 FY26 earnings • Updated Apr 18, 2026
Operating Leverage Inflection
Expected: March 2026HIGH confidence
What: Pen-G Capacity Utilization: 65% to 70%
Impact: EBITDA break-even
“We expect to ramp it up to nearly 65 to 70% by March ‘26 against the last year average of 42%.”
Geographical Expansion
Expected: End of FY26MEDIUM confidence
What: European Revenue Growth: 27%
Impact: >1 billion Euro revenue
“Consistent execution across key European markets firmly underpins our trajectory to exceed 1 billion in annual European revenue by close of FY26.”
New Product Or Brand Launch
Expected: FY27-FY29MEDIUM confidence
What: Biosimilar Pipeline: 4 approvals in EEA
Impact: Inflection point in 2029
“I believe 29 (2029) would be the inflection year for biotech. All the efforts that we have made in bringing four biosimilars into the market.”
Share Buyback As Eps Catalyst
Expected: Q1 FY27LOW confidence
What: Board Consideration: Post-April 1st
“The board will consider these and then decide in their best wisdom, depending upon the circumstances.”
European Revenue Growth of 27%
HIGH confidence
What: European Revenue Growth of 27%
“The European business maintained its strong momentum in growth, delivering 27% year-on-year revenue growth, amounting to Rs. 2,703 crores.”
Pen-G Production guidance raised
HIGH confidence
What: 6,000 MT annualized → 10,000 MT annualized
“Based on our current production level, we expect to produce more than 10,000 metric tonnes on annualised basis over the next 12 months.”
What Are the Key Risks for Aurobindo Pharma Ltd?
Earnings deceleration risks from management commentary
Eugia III facility received procedural and technical observations from the USFDA
HIGHTrigger: The facility is currently under a warning letter, and new observations could delay the lifting of that letter.
Management view: Confident of responding within 15 working days; no stoppage of production.
Monitor: regulatory
Significant depreciation of the Rupee against the USD and Euro
MEDIUMTrigger: Currency translation impacts both the top line and other expenses.
Impact: PAT impact: Other expenses rose to Rs. 2,000 crores due to translation.
Management view: Numbers reflect actual translation at average rates for the quarter.
Monitor: fx
Predatory pricing in 6APA internationally
MEDIUMTrigger: International prices fell below the cost of manufacture, impacting margins for allied products.
Impact: PAT impact: Incurred losses absorbed in EBITDA margin.
Management view: MIP implementation expected to resolve this by April.
Monitor: commodity
One-time cost of Rs
LOWTrigger: Changes in the domestic labor code required a one-time provision.
Impact: PAT impact: Rs. 65 crores hit to PAT.
Management view: One-time cost already accounted for in Q3 results.
Monitor: labor
What Is Aurobindo Pharma Ltd's Management Saying?
Key quotes from recent conference calls
“Last but not least, we are confident of achieving our internal margin target of 20%-21% for FY26, as communicated earlier. [Previous EBITDA Margin guidance]”
“The Government of India issued a notification introducing a one-year CIF on minimum import price for Pen-G, 6 APA and Amoxicillin. [Initiative: Pen-G and 6APA Minimum Import Price (MIP)]”
“The Lannett acquisition further strengthened the US business, and this is subject to regulatory approvals. [Initiative: Lannett Acquisition]”
“We remain confident of achieving EBITDA break-even in Q4 and meaningfully contribute to the bottom-line EBITDA in the next year. [Initiative: China OSD Facility Ramp-up]”
What Did Aurobindo Pharma Ltd Report This Quarter?
Headline numbers from the latest earnings call
Revenue
₹8,646 crores
YoY +8.4%QoQ +4.3%
Why: Growth was driven by continuous strong performance in European operations coupled with stable U.S. based business and growth market operations.
Revenue growth was primarily fueled by a 27% surge in the European business.
EBITDA
₹1,773 crores
YoY +9%Margin 20.5%
Why: The performance demonstrates strong operating leverage, fiscal prudence, and consistent execution of the company's strategy.
EBITDA margins improved slightly from 20.3% in Q2 to 20.5% in Q3.
PAT
₹910 crores
QoQ +7.3%
Why: Net profit was impacted by a one-time cost of Rs. 65 crores due to changes in the labour code amendment.
PAT grew sequentially despite the one-time labor code provision.
Other Highlights
• U.S. injectable sales grew 17% year-on-year.
• European revenue reached €261 million, up 27% year-on-year.
• R&D expenditure stood at ₹409 crores, representing 5% of total revenues.
What Sector Metrics Matter for Aurobindo Pharma Ltd?
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
U.S. Formulation Revenue
$420 million
QoQ +0.7%
Why: Core business saw healthy demand and volume expansion.
Europe Revenue Growth (YoY)
27%
YoY +27%
Why: Strong performance across France, Portugal, Germany, and Netherlands.
U.S. Injectable Sales Growth (YoY)
17%
YoY +17%
Why: Steady improvement supported by supply ramp-up and higher capacity utilization.
Pen-G Annualized Production
10,000 MT
QoQ +66%
Why: Ramp-up of facility and improving yield levels.
R&D as % of Revenue
5%
YoY 0%QoQ 0%
Why: Consistent focus on building a robust pipeline of high-value products.
New Product Launches (U.S.)
9 products
QoQ +50%
Why: Reflecting strong pipeline performance.
Gross Margin
59.7%
QoQ 0%
Why: Supported by softer raw material prices and business mix.
Net Capex (Quarterly)
$79 million
QoQ -25%
Why: In line with strategic priorities of enhancing manufacturing and automation.
ARV Formulation Growth (YoY)
22%
YoY +22%
Why: Driven by higher volumes and new tender wins across key markets.
China OSD Annual Capacity
2 billion units
QoQ 0%
Why: Advancing towards full capacity with EU and local approvals.
What Is Aurobindo Pharma Ltd's Management Guidance?
Forward-looking targets from management for By close of FY26
OPM Guidance
20–21%
Revenue Outlook
Exceed 1 billion in annual European revenue
Margin Outlook
REAFFIRMED
Capex Plan
USD 150 to 200 million
Maintenance and Biologics (TheraNym)
Volume
ACTIVE
Management Tone: BULLISH
Guidance Changes
RAISED
Pen-G Production: 6,000 MT annualized → 10,000 MT annualized
How Fast Is Aurobindo Pharma Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +8% | +11% | Stable |
| PAT (Net Profit) | +8% | +10% | Inflection Up |
| OPM | 21.0% | +100 bps | Stable |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 18, 2026.
Other Top Pharma - Formulators Stocks Beating Nifty 500
Frequently Asked Questions: Aurobindo Pharma Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What were Aurobindo Pharma Ltd's latest quarterly results?
Aurobindo Pharma Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: +7.6% (turning around (inflection up))
- Revenue Growth YoY: +8.4%
- Operating Margin: 21.0% (stable)
Is Aurobindo Pharma Ltd's profit growing or declining?
Aurobindo Pharma Ltd's profit is growing with an turning around (inflection up) trend.
- PAT Growth YoY: +7.6% (latest quarter)
- PAT Growth QoQ: +7.3% (sequential)
- 3-Year PAT CAGR: +9.6%
- Trend: Turning around (inflection up) — consistent growth pattern
What is Aurobindo Pharma Ltd's revenue growth trend?
Aurobindo Pharma Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +8.4%
- Revenue Growth QoQ: +4.3% (sequential)
- 3-Year Revenue CAGR: +10.6%
How is Aurobindo Pharma Ltd's operating margin trending?
Aurobindo Pharma Ltd's operating margin is stable.
- Current OPM: 21.0%
- OPM Change YoY: +1.0% basis points
- OPM Change QoQ: +1.0% basis points
What is Aurobindo Pharma Ltd's 3-year profit and revenue CAGR?
Aurobindo Pharma Ltd's long-term compounding rates
- 3-Year Profit CAGR: +9.6%
- 3-Year Revenue CAGR: +10.6%
Is Aurobindo Pharma Ltd's growth accelerating or decelerating?
Aurobindo Pharma Ltd's earnings growth is turning around (inflection up) with improving on a sequential basis.
- YoY Acceleration: +3.8% bps
- Sequential Acceleration: +4.4% bps
What is Aurobindo Pharma Ltd's trailing twelve month (TTM) performance?
Aurobindo Pharma Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹3,000 Cr
- TTM PAT Growth: -0.1% YoY
- TTM Revenue: ₹33,000 Cr
- TTM Revenue Growth: +7.3% YoY
- TTM Operating Margin: 20.5%
Is Aurobindo Pharma Ltd overvalued or undervalued?
Aurobindo Pharma Ltd appears significantly overvalued based on our fair value analysis.
- Valuation Signal: Significantly Overvalued
- Current PE: 24.5x
- Price-to-Book: 2.5x
What is Aurobindo Pharma Ltd's current PE ratio?
Aurobindo Pharma Ltd's current PE ratio is 24.5x.
- Current PE: 24.5x
- Market Cap: 86.4K Cr
- Dividend Yield: 0.27%
How does Aurobindo Pharma Ltd's valuation compare to its history?
Aurobindo Pharma Ltd's current PE is 24.5x.
- Current PE: 24.5x
- Valuation Assessment: Significantly Overvalued
What is Aurobindo Pharma Ltd's price-to-book ratio?
Aurobindo Pharma Ltd's price-to-book ratio is 2.5x.
- Price-to-Book (P/B): 2.5x
- Book Value per Share: ₹603
- Current Price: ₹1487
Is Aurobindo Pharma Ltd a fundamentally strong company?
Aurobindo Pharma Ltd is rated Average with a fundamental score of 49.31/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +8.4% (10% weight)
- PAT Growth YoY: +7.6% (10% weight)
- PAT Growth QoQ: +7.3% (10% weight)
- Margins stable (10% weight)
Is Aurobindo Pharma Ltd debt free?
Aurobindo Pharma Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹8,000 Cr
What is Aurobindo Pharma Ltd's return on equity (ROE) and ROCE?
Aurobindo Pharma Ltd's return ratios over recent years
- FY2023: ROCE 9.0%
- FY2024: ROCE 14.0%
- FY2025: ROCE 14.0%
Is Aurobindo Pharma Ltd's cash flow positive?
Aurobindo Pharma Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹4,000 Cr
- Free Cash Flow (FCF): ₹2,000 Cr
- CFO/PAT Ratio: 113% (strong cash conversion)
What is Aurobindo Pharma Ltd's dividend yield?
Aurobindo Pharma Ltd's current dividend yield is 0.27%.
- Dividend Yield: 0.27%
- Current Price: ₹1487
Who holds Aurobindo Pharma Ltd shares — promoters, FII, DII?
Aurobindo Pharma Ltd's shareholding pattern (Mar 2026)
- Promoters: 51.8%
- FII (Foreign): 15.2%
- DII (Domestic): 25.8%
- Public: 7.1%
Is promoter holding increasing or decreasing in Aurobindo Pharma Ltd?
Aurobindo Pharma Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 51.8% (Mar 2026)
- Previous Quarter: 51.8% (Dec 2025)
- Change: 0.00% (stable)
How long has Aurobindo Pharma Ltd been outperforming Nifty 500?
Aurobindo Pharma Ltd has been outperforming Nifty 500 for 10 consecutive weeks, indicating consistent outperformance.
Is Aurobindo Pharma Ltd a new momentum entry or an established outperformer?
Aurobindo Pharma Ltd is an established outperformer with 10 weeks of consecutive Nifty 500 outperformance.
What are the growth catalysts for Aurobindo Pharma Ltd?
Aurobindo Pharma Ltd has 7 key growth catalysts identified from recent earnings analysis
- Regulatory Approval Or License Win — The MIP protects domestic production from predatory international pricing.
- Operating Leverage Inflection — Ramping up from 42% average to nearly 70% will drive fixed cost absorption.
- Geographical Expansion — Strong momentum in France, Portugal, Germany, and Netherlands.
- New Product Or Brand Launch — Transitioning from development phase to real on-the-ground commercialization.
What are the key risks in Aurobindo Pharma Ltd?
Aurobindo Pharma Ltd has 4 key risks worth monitoring
- [HIGH] Eugia III facility received procedural and technical observations from the USFDA — The facility is currently under a warning letter, and new observations could delay the lifting of that letter.
- [MEDIUM] Significant depreciation of the Rupee against the USD and Euro — Currency translation impacts both the top line and other expenses.
- [MEDIUM] Predatory pricing in 6APA internationally — International prices fell below the cost of manufacture, impacting margins for allied products.
- [LOW] One-time cost of Rs — Changes in the domestic labor code required a one-time provision.
What did Aurobindo Pharma Ltd's management say in the latest earnings call?
In Q3 FY26, Aurobindo Pharma Ltd's management highlighted
- "Last but not least, we are confident of achieving our internal margin target of 20%-21% for FY26, as communicated earlier. [Previous EBITDA Margin gu..."
- "The Government of India issued a notification introducing a one-year CIF on minimum import price for Pen-G, 6 APA and Amoxicillin. [Initiative: Pen-G..."
- "The Lannett acquisition further strengthened the US business, and this is subject to regulatory approvals. [Initiative: Lannett Acquisition]"
What is Aurobindo Pharma Ltd's management guidance for growth?
Aurobindo Pharma Ltd's management has provided the following forward guidance for By close of FY26
- Revenue outlook: Exceed 1 billion in annual European revenue
- OPM guidance: 20–21%
- Capex plan: USD 150 to 200 million for Maintenance and Biologics (TheraNym)
- Management tone: bullish
- Milestone: [RAISED] Pen-G Production: 6,000 MT annualized → 10,000 MT annualized
What sector-specific metrics matter most for Aurobindo Pharma Ltd?
Aurobindo Pharma Ltd's most important sub-sector-specific KPIs from the latest concall
- U.S. Formulation Revenue: $420 million (QoQ +0.7%) — Core business saw healthy demand and volume expansion.
- Europe Revenue Growth (YoY): 27% (YoY +27%) — Strong performance across France, Portugal, Germany, and Netherlands.
- U.S. Injectable Sales Growth (YoY): 17% (YoY +17%) — Steady improvement supported by supply ramp-up and higher capacity utilization.
- Pen-G Annualized Production: 10,000 MT (QoQ +66%) — Ramp-up of facility and improving yield levels.
- R&D as % of Revenue: 5% (YoY 0%) (QoQ 0%) — Consistent focus on building a robust pipeline of high-value products.
- New Product Launches (U.S.): 9 products (QoQ +50%) — Reflecting strong pipeline performance.
Is Aurobindo Pharma Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Aurobindo Pharma Ltd may be worth studying
- Earnings growing at +7.6% YoY
- Cash flow is positive — CFO ₹4,000 Cr
What is the investment thesis for Aurobindo Pharma Ltd?
Aurobindo Pharma Ltd investment thesis summary:
Research Signals (Bull Case)
- Growth catalyst: Regulatory Approval Or License Win
Risk Factors (Bear Case)
- Appears significantly overvalued
- Key risk: Eugia III facility received procedural and technical observations from the USFDA
What is the future outlook for Aurobindo Pharma Ltd?
Aurobindo Pharma Ltd's forward outlook based on current data signals
- Earnings Trend: turning around (inflection up)
- Revenue Trend: stable
- Margin Trend: stable
- Valuation: Significantly Overvalued
- Key Catalyst: Regulatory Approval Or License Win
- Key Risk: Eugia III facility received procedural and technical observations from the USFDA
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.